-
Tytuł:
-
Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma.
-
Autorzy:
-
Wu MT; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Laboratory Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
He SY; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.
Chen SL; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Laboratory Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Li LF; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Laboratory Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
He ZQ; Department of Laboratory Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhu YY; Department of Laboratory Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
He X; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. .; Department of Laboratory Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. .
Chen H; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. .; Department of Laboratory Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. .
-
Źródło:
-
BMC cancer [BMC Cancer] 2019 Jun 04; Vol. 19 (1), pp. 538. Date of Electronic Publication: 2019 Jun 04.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: London : BioMed Central, [2001-
-
MeSH Terms:
-
C-Reactive Protein/*analysis
Carcinoma, Hepatocellular/*diagnosis
Carcinoma, Hepatocellular/*mortality
Liver Neoplasms/*diagnosis
Liver Neoplasms/*mortality
Serum Albumin, Human/*analysis
Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/analysis ; Chi-Square Distribution ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Tumor Burden ; Young Adult ; alpha-Fetoproteins/analysis
-
References:
-
Br J Cancer. 2003 Sep 15;89(6):1028-30. (PMID: 12966420)
Clin Cancer Res. 2004 Nov 1;10(21):7252-9. (PMID: 15534099)
Hepatology. 2005 Nov;42(5):1208-36. (PMID: 16250051)
Aliment Pharmacol Ther. 2005 Dec;22(11-12):1079-89. (PMID: 16305721)
Liver Int. 2007 Oct;27(8):1091-7. (PMID: 17845537)
Gastroenterology. 2008 May;134(6):1752-63. (PMID: 18471552)
Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6. (PMID: 19318937)
N Engl J Med. 2011 Sep 22;365(12):1118-27. (PMID: 21992124)
Lancet. 2012 Mar 31;379(9822):1245-55. (PMID: 22353262)
J Hepatol. 2012 Nov;57(5):1013-20. (PMID: 22732513)
BMC Cancer. 2013 Feb 15;13:78. (PMID: 23409924)
Clin Mol Hepatol. 2013 Mar;19(1):70-7. (PMID: 23593612)
Crit Rev Oncol Hematol. 2013 Oct;88(1):218-30. (PMID: 23602134)
Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):189-99. (PMID: 24220913)
Oncology. 2014;86(5-6):308-17. (PMID: 24924697)
Zhonghua Zhong Liu Za Zhi. 2014 Jun;36(6):430-4. (PMID: 25241784)
Clin Cancer Res. 2014 Dec 1;20(23):6212-22. (PMID: 25271081)
J Hepatol. 2015 Apr;62(4):848-54. (PMID: 25450201)
J Clin Oncol. 2015 Feb 20;33(6):550-8. (PMID: 25512453)
Chin J Cancer. 2015 Aug 10;34(8):335-49. (PMID: 26264146)
Ann Surg Oncol. 2016 Mar;23(3):900-7. (PMID: 26530445)
J Surg Oncol. 2016 May;113(6):621-7. (PMID: 26861568)
BMC Cancer. 2016 Feb 22;16:137. (PMID: 26907597)
Oncol Res Treat. 2016;39(5):266-71. (PMID: 27174032)
Mol Clin Oncol. 2016 Jul;5(1):83-88. (PMID: 27330772)
Liver Int. 2017 Feb;37(2):280-289. (PMID: 27501075)
Int J Mol Sci. 2016 Sep 03;17(9):. (PMID: 27598151)
Surg Endosc. 2017 Jan;31(1):445-454. (PMID: 27734201)
Oncology. 2017;93(2):136-142. (PMID: 28486226)
Sci Rep. 2017 Aug 11;7(1):7914. (PMID: 28801646)
-
Contributed Indexing:
-
Keywords: Albumin to C-reactive protein ratio; Disease-free survival; Hepatocellular carcinoma; Overall survival
-
Substance Nomenclature:
-
0 (AFP protein, human)
0 (Biomarkers, Tumor)
0 (alpha-Fetoproteins)
9007-41-4 (C-Reactive Protein)
ZIF514RVZR (Serum Albumin, Human)
-
Entry Date(s):
-
Date Created: 20190606 Date Completed: 20191211 Latest Revision: 20200225
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC6549313
-
DOI:
-
10.1186/s12885-019-5747-5
-
PMID:
-
31164099
-
Background: Despite recent advances in the treatments of hepatocellular carcinoma (HCC), the prognosis of HCC patients remains controversial. The purpose of this study was to investigate the prognostic performance of pretreatment albumin to C-reactive protein ratio (ACR) in patients with HCC.
Methods: This study included 409 initially diagnosed HCC patients retrospectively. The optimal cut-off points for distinguishing high and low ACR value was determined by the X-tile software. The chi-squared test was used for comparing the baseline clinicopathologic parameters in different groups and subgroups. The Cox regression with log-rank tests was used to analyze OS and DFS, and Kaplan-Meier curves was used to estimate the prognosis of HCC patients.
Results: Patients with lower ACR were significantly correlated with advanced clinical parameters, using a cut-off points of 5.4 (high ACR, n = 236 vs. low ACR, n = 173). Multivariate analysis demonstrated that ACR was associated with OS (HR = 0.544, 95% CI: 0.385-0.769, p = 0.001), with DFS (HR = 0.550, 95% CI: 0.392-0.772, p = 0.001). Treatment exposure (HR = 2.191; 95% CI: 1.533-3.132; p < 0.001), tumor size (HR = 1.973; 95% CI: 1.230-3.164; p = 0.005), serum AFP level (HR = 1.752; 95% CI: 1.277-2.403; p = 0.001), and TNM stage (HR = 0.470; 95% CI: 0.319-2.504; p < 0.001), were independent factors for OS in HCC patients. Treatment exposure (HR = 2.244; 95% CI: 1.590-3.166; p < 0.001), TNM stage (HR = 2.075; 95% CI: 1.436-3.000; p < 0.001), serum AFP level (HR = 1.819; 95% CI: 1.340-2.469; p = 0.001), tumor size (HR = 1.730; 95% CI: 1.113-2.689; p = 0.015), and ACR (HR = 0.550; 95% CI: 0.392-0.772; p = 0.001) were independent factors for DFS in HCC patients.
Conclusions: Pretreatment ACR is a convenient and useful parameter for HCC patients predicting OS and DFS. Lower ACR was associated with advanced TNM stage, larger tumor size, and a high concentration of AFP. These results may help to design strategies to personalize management approaches among HCC patients.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.
